Cargando…
Infliximab Reverses Suppression of Cholesterol Efflux Proteins by TNF-α: A Possible Mechanism for Modulation of Atherogenesis
Tumor necrosis factor- (TNF-) α is a proinflammatory proatherogenic cytokine. Infliximab, an anti-TNF-α monoclonal antibody, is effective in treating rheumatoid arthritis. However, its impact on cardiovascular burden and lipid transport is unclear. The present study investigates the effect of TNF-α...
Autores principales: | Voloshyna, Iryna, Seshadri, Sangeetha, Anwar, Kamran, Littlefield, Michael J., Belilos, Elise, Carsons, Steven E., Reiss, Allison B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920897/ https://www.ncbi.nlm.nih.gov/pubmed/24587984 http://dx.doi.org/10.1155/2014/312647 |
Ejemplares similares
-
Methotrexate in Atherogenesis and Cholesterol Metabolism
por: Coomes, Eric, et al.
Publicado: (2011) -
Transcriptional regulation of macrophage cholesterol efflux and atherogenesis by a long noncoding RNA
por: Sallam, Tamer, et al.
Publicado: (2018) -
Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk
por: Chan, Edwin SL, et al.
Publicado: (2007) -
Cholesterol efflux alterations in adolescent obesity: role of adipose-derived extracellular vesical microRNAs
por: Barberio, Matthew D., et al.
Publicado: (2019) -
FGF21 induces autophagy‐mediated cholesterol efflux to inhibit atherogenesis via RACK1 up‐regulation
por: Xiaolong, Lin, et al.
Publicado: (2020)